×
S&P 500   3,890.12 (+1.17%)
DOW   31,261.03 (+0.72%)
QQQ   294.09 (+1.83%)
AAPL   145.68 (+1.93%)
MSFT   267.80 (+0.60%)
META   171.77 (+1.18%)
GOOGL   2,359.76 (+2.98%)
AMZN   116.44 (+1.85%)
TSLA   733.92 (+5.57%)
NVDA   157.97 (+4.41%)
NIO   22.51 (+8.07%)
BABA   123.25 (+3.47%)
AMD   79.00 (+4.84%)
MU   58.38 (+1.76%)
CGC   2.73 (+3.02%)
T   21.12 (+0.14%)
GE   62.43 (+1.40%)
F   11.59 (+4.79%)
DIS   96.93 (+0.88%)
AMC   14.14 (+12.49%)
PFE   53.17 (+0.80%)
PYPL   74.55 (+1.79%)
NFLX   188.58 (+2.46%)
S&P 500   3,890.12 (+1.17%)
DOW   31,261.03 (+0.72%)
QQQ   294.09 (+1.83%)
AAPL   145.68 (+1.93%)
MSFT   267.80 (+0.60%)
META   171.77 (+1.18%)
GOOGL   2,359.76 (+2.98%)
AMZN   116.44 (+1.85%)
TSLA   733.92 (+5.57%)
NVDA   157.97 (+4.41%)
NIO   22.51 (+8.07%)
BABA   123.25 (+3.47%)
AMD   79.00 (+4.84%)
MU   58.38 (+1.76%)
CGC   2.73 (+3.02%)
T   21.12 (+0.14%)
GE   62.43 (+1.40%)
F   11.59 (+4.79%)
DIS   96.93 (+0.88%)
AMC   14.14 (+12.49%)
PFE   53.17 (+0.80%)
PYPL   74.55 (+1.79%)
NFLX   188.58 (+2.46%)
S&P 500   3,890.12 (+1.17%)
DOW   31,261.03 (+0.72%)
QQQ   294.09 (+1.83%)
AAPL   145.68 (+1.93%)
MSFT   267.80 (+0.60%)
META   171.77 (+1.18%)
GOOGL   2,359.76 (+2.98%)
AMZN   116.44 (+1.85%)
TSLA   733.92 (+5.57%)
NVDA   157.97 (+4.41%)
NIO   22.51 (+8.07%)
BABA   123.25 (+3.47%)
AMD   79.00 (+4.84%)
MU   58.38 (+1.76%)
CGC   2.73 (+3.02%)
T   21.12 (+0.14%)
GE   62.43 (+1.40%)
F   11.59 (+4.79%)
DIS   96.93 (+0.88%)
AMC   14.14 (+12.49%)
PFE   53.17 (+0.80%)
PYPL   74.55 (+1.79%)
NFLX   188.58 (+2.46%)
S&P 500   3,890.12 (+1.17%)
DOW   31,261.03 (+0.72%)
QQQ   294.09 (+1.83%)
AAPL   145.68 (+1.93%)
MSFT   267.80 (+0.60%)
META   171.77 (+1.18%)
GOOGL   2,359.76 (+2.98%)
AMZN   116.44 (+1.85%)
TSLA   733.92 (+5.57%)
NVDA   157.97 (+4.41%)
NIO   22.51 (+8.07%)
BABA   123.25 (+3.47%)
AMD   79.00 (+4.84%)
MU   58.38 (+1.76%)
CGC   2.73 (+3.02%)
T   21.12 (+0.14%)
GE   62.43 (+1.40%)
F   11.59 (+4.79%)
DIS   96.93 (+0.88%)
AMC   14.14 (+12.49%)
PFE   53.17 (+0.80%)
PYPL   74.55 (+1.79%)
NFLX   188.58 (+2.46%)
NASDAQ:STRO

Sutro Biopharma Stock Forecast, Price & News

$5.85
+0.41 (+7.54%)
(As of 07/7/2022 01:10 PM ET)
Add
Compare
Today's Range
$5.46
$5.87
50-Day Range
$3.41
$6.60
52-Week Range
$3.33
$23.70
Volume
14,070 shs
Average Volume
1.73 million shs
Market Capitalization
$274.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
323.2% Upside
$24.33 Price Target
Short Interest
Bearish
11.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.86mentions of Sutro Biopharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.27) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.26 out of 5 stars

Medical Sector

139th out of 1,433 stocks

Biological Products, Except Diagnostic Industry

19th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Sutro Biopharma logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock News Headlines

Short Volatility Alert: Sutro Biopharma, Inc.
Sutro Biopharma, Inc. Common Stock (STRO)
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/07/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+316.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-105,540,000.00
Net Margins
-215.16%
Pretax Margin
-215.16%

Debt

Sales & Book Value

Annual Sales
$61.88 million
Book Value
$5.46 per share

Miscellaneous

Free Float
44,540,000
Market Cap
$274.54 million
Optionable
Not Optionable
Beta
0.91














Sutro Biopharma Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month price targets for Sutro Biopharma's stock. Their STRO stock forecasts range from $16.00 to $30.00. On average, they predict Sutro Biopharma's share price to reach $24.33 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price.
View analysts' price targets for Sutro Biopharma
or view top-rated stocks among Wall Street analysts.

How has Sutro Biopharma's stock price performed in 2022?

Sutro Biopharma's stock was trading at $14.88 at the beginning of 2022. Since then, STRO stock has decreased by 60.8% and is now trading at $5.84.
View the best growth stocks for 2022 here
.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Sutro Biopharma
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.08. Sutro Biopharma had a negative net margin of 215.16% and a negative trailing twelve-month return on equity of 42.97%.
View Sutro Biopharma's earnings history
.

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • Mr. William J. Newell J.D., CEO & Director (Age 64, Pay $1.06M)
  • Mr. Edward C. Albini, CFO & Sec. (Age 64, Pay $596.4k)
  • Dr. Trevor J. Hallam, Pres of Research & Chief Scientific Officer (Age 63, Pay $882.83k)
  • Dr. Arturo M. Molina FACP, M.D., M.S., MS, Chief Medical Officer (Age 63, Pay $691.83k)
  • Ms. Jane Chung R.Ph., Chief Commercial Officer (Age 51, Pay $832.52k)
  • Dr. James R. Swartz Ph.D., Sc.D., Founder
  • Dr. Shabbir T. Anik, Chief Technical Operations Officer (Age 69)
  • Ms. Annie J. Chang M.B.A., VP of Investor Relations
  • Mr. David Pauling J.D., M.A., Gen. Counsel
  • Ms. Linda A. Fitzpatrick, Chief People & Communications Officer (Age 65)

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $5.84.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $274.07 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Sutro Biopharma have?

Sutro Biopharma employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for Sutro Biopharma is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.